Targeting the Carbonic Anhydrase Enzyme with Synthesized Benzenesulfonamide Derivatives: Inhibiting Tumor Growth
DOI:
https://doi.org/10.22317/jcms.v9i4.1404Keywords:
In Silico, Triazoles, Moieties, Carbonic Anhydrase InhibitorsAbstract
Objectives: To assess the anticancer effects of recently developed compounds, Sa, Sb, Sc, and Sd. These compounds were designed to specifically target the carbonic anhydrase enzyme in solid tumors.
Methods: The chemical synthesis involved the use of sulfanilamide, chloroacetyl chloride, GABA, thionyl chloride, methanol, hydrazine hydrate, potassium hydroxide, carbon disulfide, and benzyl chloride derivatives. Docking studies were conducted using the MOE software program version 2015.10, and cytotoxic activity was predicted using the MTT assay.
Results: The newly synthesized compounds exhibited notable antineoplastic activity in both in silico and cell line investigations. Although they showed a significant difference in potency compared to cisplatin against cancer cells, they also demonstrated significant differences in toxicity towards normal cells. When compared to acetazolamide, compounds Sb displayed an IC50 = 28.41 μM, which was significantly different, and compound Sd showed a non-significant difference with an IC50 = 61.20 μM against MCF7 cells. Additionally, Sb and Sd demonstrated significant difference in toxicity, with IC50 = 279.02 μM and 194.00 μM, respectively, against MCF10a cells. These findings indicate a significant difference compared to acetazolamide for the Sb compound and suggest that the synthesized compounds hold potential for further development as antineoplastic agents. Furthermore, the results from the cell line study align with the in silico study, where both compounds Sb and Sd exhibited higher S scores compared to acetazolamide, implying a stronger binding affinity with the receptor's catalytic site. The presence of a substituted 1,2,4-triazole ring in these compounds contributed to enhanced flexibility and improved interaction with the receptor.
Conclusion: A new synthesized compounds exhibited cytotoxicity and demonstrated inhibitory potencies against carbonic anhydrase.
References
Mathur, G., S. Nain, and P.K. Sharma, Cancer: an overview. Acad. J. Cancer Res, 2015. 8(1).
Tuğrak, M., et al., Synthesis and biological evaluation of new pyrazolebenzene-sulphonamides as potentialanticancer agents and hCA I and II inhibitors. Turkish Journal of Chemistry, 2021. 45(3): p. 528-539.
Nemr, M.T., et al., Design, synthesis and mechanistic study of new benzenesulfonamide derivatives as anticancer and antimicrobial agents via carbonic anhydrase IX inhibition. RSC advances, 2021. 11(42): p. 26241-26257.
Al Tameemi, W., et al., Hypoxia-modified cancer cell metabolism. Frontiers in cell and developmental biology, 2019. 7: p. 4.
Nguyen, P.L., et al., Suppression of Tumor Growth and Cell Migration by Indole-Based Benzenesulfonamides and Their Synergistic Effects in Combination with Doxorubicin. International Journal of Molecular Sciences, 2022. 23(17): p. 9903.
Kumar, S., et al., Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors. European Journal of Medicinal Chemistry, 2021. 209: p. 112923.
Supuran, C.T., Carbonic anhydrase inhibitors. Bioorganic & medicinal chemistry letters, 2010. 20(12): p. 3467-3474.
Angeli, A., et al., New sulfanilamide derivatives incorporating heterocyclic carboxamide moieties as carbonic anhydrase inhibitors. Pharmaceuticals, 2021. 14(8): p. 828.
Mboge, M.Y., et al., Carbonic anhydrases: role in pH control and cancer. Metabolites, 2018. 8(1): p. 19.
Sedlakova, O., et al., Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Frontiers in physiology, 2014. 4: p. 400.
Tafreshi, N.K., et al., Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. Carbonic anhydrase: Mechanism, regulation, links to disease, and industrial applications, 2014: p. 221-254.
Nada, H., et al., 4-Anilinoquinazoline-based benzenesulfonamides as nanomolar inhibitors of carbonic anhydrase isoforms I, II, IX, and XII: design, synthesis, in-vitro, and in-silico biological studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022. 37(1): p. 994-1004.
Scozzafava, A., et al., Anticancer and antiviral sulfonamides. Current medicinal chemistry, 2003. 10(11): p. 925-953.
Supuran, C.T., A. Casini, and A. Scozzafava, Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Medicinal Research Reviews, 2003. 23(5): p. 535-558.
Abbate, F., et al., Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorganic & medicinal chemistry letters, 2004. 14(1): p. 217-223.
Cornelio, B., et al., 4-Arylbenzenesulfonamides as human carbonic anhydrase Inhibitors (hCAIs): Synthesis by Pd nanocatalyst-mediated Suzuki–Miyaura reaction, enzyme inhibition, and X-ray crystallographic studies. Journal of medicinal chemistry, 2016. 59(2): p. 721-732.
Bonardi, A., et al., Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: improving ligand/isoform matching and selectivity of action. Journal of Medicinal Chemistry, 2020. 63(13): p. 7422-7444.
Li, Y., et al., Thiadiazole—A promising structure in medicinal chemistry. ChemMedChem, 2013. 8(1): p. 27-41.
Al-Mulla, A., A review: biological importance of heterocyclic compounds. Der Pharma Chemica, 2017. 9(13): p. 141-147.
Asif, M., Anti-neuropathic and anticonvulsant activities of various substituted triazoles analogues. Chem Int, 2015. 1(4): p. 174-183.
Dai, J., et al., Synthesis methods of 1, 2, 3-/1, 2, 4-triazoles: A review. Frontiers in Chemistry, 2022. 10.
Gadhave, P.P., et al., Current biological and synthetic profile of triazoles: A review. Annals Biol. Res, 2010. 1(1): p. 82-89.
Kaur, R., et al., Recent developments on 1, 2, 4-triazole nucleus in anticancer compounds: a review. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2016. 16(4): p. 465-489.
Billah, M.M., et al., Determination of the presence and pharmacokinetic profile of ciprofloxacin by TLC and HPLC method respectively in broiler chicken after single oral administration. The Journal of Antibiotics, 2014. 67(11): p. 745-748.
Mina, S., et al., Synthesis and biological investigation of some novel sulfonamide and amide derivatives containing coumarin moieties. 2014.
Li, J. and Y. Sha, A convenient synthesis of amino acid methyl esters. Molecules, 2008. 13(5): p. 1111-1119.
Park, H.-S., et al., Synthesis and characterization of novel hydantoins as potential COX-2 inhibitors: 1, 5-Diarylhydantoins. Bulletin of the Korean Chemical Society, 2007. 28(5): p. 751-757.
Jubie, S., et al., Synthesis and biological evaluation of some schiff bases of [4-(amino)-5-phenyl-4H-1, 2, 4-triazole-3-thiol]. Pak. J. Pharm. Sci, 2011. 24(2): p. 109-112.
Husain, A., M.A. Naseer, and M. Sarafroz, Synthesis and anticonvulsant activity of some novel fused heterocyclic 1, 2, 4-triazolo-[3, 4-b]-1, 3, 4-thiadiazole derivatives. Acta Pol Pharm, 2009. 66(2): p. 135-40.
Pavia, D.L., et al., Introduction to spectroscopy. 2014: Cengage learning.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
